Menu
← Oncology Approval Tracker
FDA DECISION ·
Romvimza
vimseltinib · Deciphera Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with symptomatic tenosynovial giant cell tumor when surgical removal could worsen physical function or cause severe morbidity.
LAMPGEN ANALYSIS
Why it matters
A CSF1R inhibitor offers systemic treatment for a symptomatic, generally nonmalignant joint tumor when surgery carries substantial risk.
What research teams should watch
Record the surgical assessment and use a consistent approach to tracking joint function, symptoms, and imaging.
PRIMARY RECORDS